ISDA

Deposition Date 2020-09-19

Release Date 2020-10-07

Last Version Date 2024-11-20

Entry Detail

PDB ID:

7D3I

Keywords:

VIRAL PROTEIN

Title:

Crystal structure of SARS-CoV-2 main protease in complex with MI-23

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2 (Taxon ID: 2697049)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.00 Å

R-Value Free:

0.20

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:3C-like proteinase
Chain IDs:A
Chain Length:306
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTD1 Pfam ID:PF05409

Ligand Molecules

GQU

TRS

Primary Citation

SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model.

Qiao, J, Li, Y.S, Zeng, R, Liu, F.L, Luo, R.H, Huang, C, Wang, Y.F, Zhang, J, Quan, B, Shen, C, Mao, X, Liu, X, Sun, W, Yang, W, Ni, X, Wang, K, Xu, L, Duan, Z.L, Zou, Q.C, Zhang, H.L, Qu, W, Long, Y.H, Li, M.H, Yang, R.C, Liu, X, You, J, Zhou, Y, Yao, R, Li, W.P, Liu, J.M, Chen, P, Liu, Y, Lin, G.F, Yang, X, Zou, J, Li, L, Hu, Y, Lu, G.W, Li, W.M, Wei, Y.Q, Zheng, Y.T, Lei, J, Yang, S.Show

Science 371 1374 1378 (2021)

PMID: 33602867 DOI: 10.1126/science.abf1611

Abstact

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continually poses serious threats to global public health. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing Mpro inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals. All compounds inhibited SARS-CoV-2 Mpro activity in vitro, with 50% inhibitory concentration values ranging from 7.6 to 748.5 nM. The cocrystal structure of Mpro in complex with MI-23, one of the most potent compounds, revealed its interaction mode. Two compounds (MI-09 and MI-30) showed excellent antiviral activity in cell-based assays. In a transgenic mouse model of SARS-CoV-2 infection, oral or intraperitoneal treatment with MI-09 or MI-30 significantly reduced lung viral loads and lung lesions. Both also displayed good pharmacokinetic properties and safety in rats.

Legend

Protein

Chemical

Disease

Primary Citation of related structures